Drug Type Autologous CAR-T |
Synonyms CLL1-CD33 cCAR T cells (iCell Gene Therapeutics), CLL1-CD33 cCART cell therapy, CLL1-CD33-CCAR |
Target |
Action modulators |
Mechanism CD33 modulators(Myeloid cell surface antigen CD33 modulators), CLL-1 modulators(C-Type lectin domain family 12 member A modulators), Gene transference(Gene transference) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingEarly Phase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Myeloid Leukemia | Phase 1 | China | 01 Mar 2018 | |
Anemia, Refractory, With Excess of Blasts | Phase 1 | China | 01 Mar 2018 | |
Chronic Myelogenous Leukemia | Phase 1 | China | 01 Mar 2018 | |
Myeloproliferative Disorders | Phase 1 | China | 01 Mar 2018 |